Corcept Therapeutics Incorporated
CORT
$73.06
-$3.59-4.68%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 741.17M | 716.08M | 685.45M | 675.04M | 628.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 741.17M | 716.08M | 685.45M | 675.04M | 628.56M |
| Cost of Revenue | 13.39M | 11.66M | 10.75M | 10.38M | 9.30M |
| Gross Profit | 727.78M | 704.42M | 674.70M | 664.66M | 619.25M |
| SG&A Expenses | 401.86M | 351.63M | 314.71M | 280.32M | 244.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 675.60M | 614.13M | 574.58M | 537.59M | 484.70M |
| Operating Income | 65.57M | 101.95M | 110.87M | 137.45M | 143.86M |
| Income Before Tax | 88.51M | 126.21M | 136.12M | 161.49M | 166.34M |
| Income Tax Expenses | -17.60M | -7.44M | 2.12M | 20.28M | 24.52M |
| Earnings from Continuing Operations | 106.11 | 133.66 | 133.99 | 141.21 | 141.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 106.11M | 133.66M | 133.99M | 141.21M | 141.82M |
| EBIT | 65.57M | 101.95M | 110.87M | 137.45M | 143.86M |
| EBITDA | 66.71M | 103.12M | 111.83M | 138.25M | 144.59M |
| EPS Basic | 1.01 | 1.27 | 1.28 | 1.35 | 1.36 |
| Normalized Basic EPS | 0.53 | 0.76 | 0.82 | 0.98 | 1.01 |
| EPS Diluted | 0.88 | 1.13 | 1.16 | 1.24 | 1.26 |
| Normalized Diluted EPS | 0.46 | 0.67 | 0.74 | 0.90 | 0.93 |
| Average Basic Shares Outstanding | 415.41M | 415.23M | 414.24M | 412.92M | 411.74M |
| Average Diluted Shares Outstanding | 478.20M | 472.49M | 463.25M | 453.34M | 445.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |